I don't think anybody will mistake KM for P.T. Barnum. It looks like his expertise is in sales and marketing, which is a shift from JT obviously, but the levers he pulls are those of the kind you cannot see.
He tried to make it sound during the last earnings call like Amarin is trying to work behind the scenes with insurers, doctors, pharmacists and others to change the default move in the industry away from generics, particularly as it pertains to Vascepa.
But it's starting to look like his operating style is more like JT than some of us might have liked. Minimal press releases. No free publicity through traditional media, which is unfortunate because I suspect that's a better way to reach the eyes and ears of most doctors than through trade publications and organizations that doctors should pay attention to but probably don't.
News 
Market Data 
Discover 
